Q-omics provides the consensus-scored SOX18 profile across patient tissues and cancer cell-line models. SOX18 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SOX18 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, SOX18 RNA expression shows 14,094 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where SOX18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SOX18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SOX18 survival associations across molecular data types. SOX18 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SOX18 RNA expression–survival associations across cancer types. High SOX18 expression shows unfavorable associations in KIRP, MESO, UCS, UVM and LUSC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SOX18 RNA expression.
This table summarizes SOX18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SOX18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SOX18 shows lower tumor expression in KIRP, LUAD, LUSC and KICH and higher tumor expression in HNSC and LIHC. The KIRP box plot shows higher SOX18 RNA expression in normal versus tumor tissue (log2 FC = −2.025, t-test p < 0.001).
This table shows molecular features associated with SOX18 in patient tissues and cancer cell lines. In patient samples, SOX18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SOX18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
